IL-2 Mutein Selective Receptor Binding for Autoimmune Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is an unmet need for IL-2 muteins that can selectively activate IL-2R signals in distinct cell types to treat immune-mediated diseases, particularly autoimmune and inflammatory diseases, with a focus on binding selectively to the IL-2 receptor α subunit to avoid activation of CD8+ T cells.
Innovation Solution
Development of IL-2 muteins that specifically bind to the IL-2 receptor α subunit without measurable binding to the IL-2 receptor β subunit, incorporating specific amino acid substitutions such as D to N at position 19 and P to R at position 33, along with optional additional substitutions like E to S at position 67, V to A at position 68, N to R at position 70, and Q to P at position 73, to achieve selective activation of T regulatory cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If IL-2 muteins bind to both IL-2R α subunit and IL-2R β subunit, then broad immune cell activation is achieved, but selective activation of T regulatory cells cannot be achieved
Solution Approach 1:
The patent applies local quality by introducing specific amino acid substitutions (D19N, P33R, and optionally E67S, V68A, N70R, Q73P) at critical binding positions in the IL-2 mutein sequence. These localized changes modify the binding interface to preferentially interact with the IL-2R α subunit while reducing affinity for the IL-2R β subunit, thereby achieving selective activation of T regulatory cells that express high levels of the α subunit.
Solution Approach 2:
The patent employs parameter changes by systematically varying the amino acid sequence parameters of the IL-2 mutein. Through site-directed mutagenesis at positions 19, 33, 67, 68, 70, and 73, the binding characteristics of the mutein are tuned to achieve differential affinity for different IL-2R subunit compositions, enabling selective biological activity in desired cell types.
2Object-affected harmful factors
If IL-2 muteins activate CD8+ T cells through IL-2R β subunit binding, then immune activation is enhanced, but autoimmune and inflammatory diseases cannot be treated
Solution Approach 1:
The patent applies the taking out principle by extracting the binding interaction with the IL-2R β subunit through specific amino acid substitutions. The D19N and P33R mutations eliminate or significantly reduce the ability of the IL-2 mutein to bind to the β subunit, thereby preventing activation of CD8+ T cells and other immune cells that rely on β subunit-containing receptors, while preserving therapeutic activity through selective α subunit binding.
3Manufacturing precision
If wild-type IL-2 is used for treatment, then immune system modulation is achieved, but lack of selective cell type activation limits therapeutic precision
Solution Approach 1:
The patent applies segmentation by functionally dividing the IL-2 receptor signaling pathways based on subunit composition. By designing muteins that selectively bind to specific subunit combinations (particularly the α subunit), the therapy targets distinct signaling pathways in different cell types, separating the therapeutic effects on T regulatory cells from effects on other immune cells that would be activated through β subunit-containing receptors.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These IL-2 muteins enable selective activation of T regulatory cells while avoiding activation of CD8+ T cells, providing a therapeutic approach for immune-mediated diseases by modulating IL-2 signaling effectively.
Implementation Method 1
IL-2 muteins that bind to the IL-2 receptor a subunit but do not have measurable binding to the IL-2 receptor β subunit
Data Source
AI summary
Provided herein are IL-2 muteins that bind to IL-2 receptor subunit but do not have measurable binding to IL-2 receptor subunit. Also provided are compositions, kits, methods, and uses involving such IL-2 muteins.